Acadia Pharmaceuticals Inc

+0.66 (+4.03%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.75B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$140.15 Million
Adjusted EPS-$0.18
See more estimates
10-Day MA$16.81
50-Day MA$16.48
200-Day MA$19.89
See more pivots

Acadia Pharmaceuticals Inc Stock, NASDAQ:ACAD

12830 El Camino Real, Suite 400, San Diego, California 92130-3331
United States of America
Phone: +1.858.558.2871
Number of Employees: 514


ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.